TB-500

Thymosin beta-4 fragment discussed for recovery support, with overall limited human evidence.

PreclinicalUnapprovedInjectableRecovery

Key facts

Common routesSubcutaneous, intramuscular

Half-life2-3 days (community estimate)

Typical range2-5 mg/week

Résumé

TB-500 is marketed as a synthetic fragment of thymosin beta-4 and is commonly discussed for tissue recovery and resilience. For TB-500 itself, controlled human evidence remains thin; much of the conversation relies on animal data, mechanism hypotheses, and anecdotal reports.

This page summarizes the current research landscape; benefit and risk framing should stay conservative.

Notes sur le mécanisme

Cell migration and repair signaling

Thymosin beta-4 related research describes effects on actin dynamics, cell migration, and wound-repair pathways. Direct translation to TB-500 in humans remains uncertain.

Inflammation and tissue response

Preclinical models suggest possible effects on inflammatory tone and repair environment. Strong RCT data for human musculoskeletal outcomes is lacking.

Schémas de dosage

Loading and repair phases

Community protocols are often discussed around 2-5 mg per week split across 1-3 injections.

This is not a clinical standard, only observed practice with high variability.

Maintenance approaches

Some users shift to less frequent injections after loading phases. Efficacy and safety of these patterns are not well validated.

Aperçu des données

Evidence for TB-500 itself is mostly preclinical. Human studies more often involve full-length thymosin beta-4 or different indications (e.g., wound settings), which limits direct extrapolation.

Preclinical signal

Animal and mechanistic work suggests pro-repair signals, but does not provide a reliable human effect size.

Human signal

High-quality interventional data for TB-500 is missing; available human literature primarily evaluates TB4.

Considérations de sécurité

Because TB-500 is not an approved human medicine, product quality, purity, and long-term safety remain key uncertainties.

Common cautions

Aucun médicament TB-500 approuvé par la FDA pour usage humain
Qualité et pureté variables dans l'offre de peptides non régulée
Interdit dans le sport contrôlé selon la WADA S2 (dérivés de la thymosine-β4)